The company is relying on several building blocks to return to growth.
Some companies are making an awful lot of money filling vital social and medical needs. Five investment experts give their stock picks for the rising demand for healthcare properties.
Shares of the Botox competitor could correct/consolidate after a recent surge.
With the stock split a fresh look at the split adjusted stock is now in order.
Healthcare is attracting some very healthy competition among mega-cap names.
Teladoc looks like it is ready to move higher.
There's a lot of runway left to adjust guidance numbers moving forward.
While the ongoing litigation could be seen as a deterrent to investment, I think the more interesting story is its upcoming AFib detection study with Apple.
Experienced traders could approach the long side carefully.
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.